Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2A | P28223 | 20/20 | 0.62 |
| ▸ | HTR2C | P28335 | 20/20 | 0.62 |
| ▸ | HTR2B | P41595 | 20/20 | 0.62 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.62 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5763193 | 1.00 | HTR2A (0.62) | HTR2AHTR2CHTR2BKCNH2 | |
| SCHEMBL5763197 | 1.00 | HTR2A (0.62) | HTR2AHTR2CHTR2BKCNH2 | |
| SCHEMBL5761945 | 0.77 | HTR2A (1.00) | HTR2AHTR2CHTR2BKCNH2 | |
| SCHEMBL6639285 | 0.77 | HTR2A (1.00) | HTR2AHTR2CHTR2BKCNH2 | |
| SCHEMBL31022237 | 0.76 | HTR2A (0.42) | HTR2AHTR2CHTR2BKCNH2 | |
| SCHEMBL5763203 | 0.75 | HTR2A (1.00) | HTR2AHTR2CHTR2BKCNH2 | |
| SCHEMBL5759856 | 0.75 | HTR2A (1.00) | HTR2AHTR2CHTR2BKCNH2 | |
| SCHEMBL5762719 | 0.75 | HTR2A (1.00) | HTR2AHTR2CHTR2BKCNH2 | |
| SCHEMBL6643670 | 0.75 | HTR2A (1.00) | HTR2AHTR2CHTR2BKCNH2 | |
| SCHEMBL5761282 | 0.75 | HTR2A (1.00) | HTR2AHTR2CHTR2BKCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7098337-B2 | 1,2,3,4,9,9a-hexahydro-2,4a,5-triaza-fluorene and 1,2,3,4-tetrahydro-2,4a,5-triaza-fluorene derivatives | HOFFMANN-LA ROCHE INC. (US) | 2006-08-29 | — | — | US | claimed |
| US-20030207888-A1 | Piperazine derivatives | F.HOFFMANN-LA ROCHE AG (CH) | 2003-11-06 | — | — | US | claimed |
| US-7098337-B2 | 1,2,3,4,9,9a-hexahydro-2,4a,5-triaza-fluorene and 1,2,3,4-tetrahydro-2,4a,5-triaza-fluorene derivatives | HOFFMANN-LA ROCHE INC. (US) | 2006-08-29 | — | — | US | disclosed |
| EP-1472255-B1 | AZA-ARYLPIPERAZINES | HOFFMANN LA ROCHE (CH) | 2006-03-01 | — | — | EP | disclosed |
| US-20030207888-A1 | Piperazine derivatives | F.HOFFMANN-LA ROCHE AG (CH) | 2003-11-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030207888-A1 | Piperazine derivatives | GPR119, CPT1B, CYP2E1 | HTR2A 747/4885HTR2C 409/4885HTR2B 630/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.